IntelliPharmaCeutics (IPCI) Rexista NDA Filing Expected, But 'Very Good News' - Maxim Group

November 25, 2016 11:17 AM EST
Get Alerts IPCI Hot Sheet
Price: $2.80 +3.32%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade IPCI Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Maxim Group analyst Jason Kolbert reiterated a Buy rating and $6 price target on IntelliPharmaCeutics International (NASDAQ: IPCI) after the company announced the filing (NDA) for Rexista (abuse-deterrent oxycodone) extended release tablets (10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg strengths). While this was highly expected we view this as very good news for the company.

Kolbert highlighted:

  • The submission also includes a comprehensive array of abuse-deterrent studies conducted to support abuse-deterrent label claims related to abuse of drug by oral, intra-nasal and intravenous pathways, having reference to the FDA's "Abuse-Deterrent Opioids — Evaluation and Labelling" guidance published in April 2015.
  • The abuse-deterrent properties incorporated into Rexista are designed to make the product unlikable and discourage or make it more difficult to manipulate for the purpose of abuse or misuse via common routes of administration including: ingestion following chewing, licking or crushing; insufflation; inhalation; or injection.
  • The Company previously announced the results of a food effect study which showed that Rexista can be administered with or without a meal (i.e., no food effect), providing another point of differentiation from currently marketed oral oxycodone extended release products.
  • Conclusion. The NDA filing is positive news. The next step will be acceptance (60 days) for Rexista, followed by the PDUFA (6 months from acceptance) date, setting the stage for a partnership opportunity.

For an analyst ratings summary and ratings history on IntelliPharmaCeutics International click here. For more ratings news on IntelliPharmaCeutics International click here.

Shares of IntelliPharmaCeutics International closed at $3.00 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

Maxim Group, PDUFA

Add Your Comment